EZH2 and cancer: Mechanisms underlying EZH2 hyperactivity have been identified in other cancers and include mutation of EZH2 itself which causes over-activation of its histone modifying capacities and DNA hypermethylator phenotypes that are associated with poor outcome, chemo- resistance and highly aggressive tumour phenotypes.